Zometa and Transitional cell carcinoma - a phase IV clinical study of FDA data

Summary:

Transitional cell carcinoma is reported as a side effect among people who take Zometa (zoledronic acid), especially for people who are female, 60+ old, have been taking the drug for 1 - 2 years also take Digoxin, and have Cardiac failure congestive.

The phase IV clinical study analyzes which people have Transitional cell carcinoma when taking Zometa. It is created by eHealthMe based on reports of 71,074 people who have side effects when taking Zometa from the FDA, and is updated regularly.

What is Zometa?

Zometa has active ingredients of zoledronic acid. It is often used in multiple myeloma. eHealthMe is studying from 71,434 Zometa users. Check the latest studies of Zometa.

What is Transitional cell carcinoma?

Transitional cell carcinoma (cancer tumour inner most layer of urinary system) is found to be associated with 186 drugs and 268 conditions by eHealthMe. Check the latest studies of Transitional cell carcinoma.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

71,074 people reported to have side effects when taking Zometa.
Among them, 37 people (0.05%) have Transitional cell carcinoma.

Could Zometa cause Transitional cell carcinoma?

Among these 37 people:

How long have people been on Zometa when they have Transitional cell carcinoma? *

What is the gender of people who have Transitional cell carcinoma when taking Zometa? *

female: 62.16 %
male: 37.84 %

What is the age of people who have Transitional cell carcinoma when taking Zometa? *

What are other drugs people take besides Zometa? *

What are other side effects people have besides Transitional cell carcinoma? *

Pain: 34 people, 91.89%
Stress And Anxiety: 33 people, 89.19%
Osteomyelitis (infection of bone): 30 people, 81.08%
Fall: 28 people, 75.68%
Diarrhea: 26 people, 70.27%
Nausea (feeling of having an urge to vomit): 24 people, 64.86%
Osteonecrosis Of Jaw (death of bone of jaw): 23 people, 62.16%
Injury: 22 people, 59.46%
Bone Disorder: 22 people, 59.46%
Abdominal Pain: 22 people, 59.46%

What are the existing conditions these people have? *

High Blood Pressure: 9 people, 24.32%
Depression: 9 people, 24.32%
Cardiac Failure Congestive: 9 people, 24.32%
Metastases To Bone (cancer spreads to bone): 7 people, 18.92%
Pain: 6 people, 16.22%
The Flu (the flu is caused by an influenza virus): 2 people, 5.41%
Burning Sensation: 2 people, 5.41%
Diabetes: 1 person, 2.70%

* Approximation only. Some reports may have incomplete information.

Do you take Zometa and have Transitional cell carcinoma?

- Check whether Transitional cell carcinoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zometa:

Zometa (71,434 reports)

Browse all side effects of Zometa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Transitional cell carcinoma:

Transitional cell carcinoma (186 drugs)

Browse all the conditions that are associated with Transitional cell carcinoma:

Transitional cell carcinoma (268 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on zoledronic acid (the active ingredients of Zometa) and Zometa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.